WO2014084427A1

WO2014084427A1 - Composition comprising alginic acid for preventing or treating osteoarthritis

Info

Publication number: WO2014084427A1
Application number: PCT/KR2012/010315
Authority: WO
Inventors: 오석중; 김광윤
Original assignee: 주식회사 이코바이오
Priority date: 2012-11-30
Filing date: 2012-11-30
Publication date: 2014-06-05

Abstract

The present invention relates to a composition comprising alginic acid, as an active ingredient, for treating or preventing osteoarthritis or osteoporosis. The composition for treating or preventing osteoarthritis or osteoporosis may be a pharmaceutical composition. Further, the present invention relates to a food composition comprising alginic acid, as an active ingredient, for alleviating or preventing osteoarthritis or osteoporosis. The composition of the present invention is identified as having an optimum condition for treating, preventing or alleviating osteoarthritis or osteoporosis in terms of the molecular weight of the alginic acid and mannuronate and guluronate. The composition of the present invention comprises alginic acid, as an active ingredient, which is harmless to humans, and therefore has no side effects and exhibits excellent effects in treating osteoarthritis or osteoporosis. Thus, the composition of the present invention can be effectively used in treating osteoarthritis or osteoporosis.

Description

Osteoarthritis prevention or treatment composition containing alginic acid

The present invention relates to a composition for preventing or treating osteoarthritis comprising a plant extract as an active ingredient.

Cartilage is an elastic tissue that connects two bones to each other, imparts mobility to joints, and plays a role in shock relaxation. In particular, articular cartilage comprises chondrocytes embedded in a matrix of proteoglycan and type II collagen as connective tissue.

When the cartilage tissue is damaged, direct friction between bones, stiffness of joints, gradual degradation of articular cartilage movement, or frequent pain in the cartilage area may be caused.

Joint disease caused by damage to the cartilage tissue, in particular osteoarthritis is a disease accompanied by a loss of cartilage function, one of the most common arthritis symptoms, many people are known to have the symptoms of osteoarthritis.

The osteoarthritis is known under several different names, for example, degenerative joint disease, osteoarthritis, hypertrophic arthritis, or degenerative arthritis. The osteoarthritis may be characterized by chronic progressive destruction of cartilage tissue in major joints such as fingers, elbows, knees or ankles.

Although the initial etiology of osteoarthritis is not clearly known, cartilage destruction is generally caused by changes or imbalances in metabolic mechanisms related to assimilation and catabolism in the articular cartilage matrix.

In articular diseases such as osteoarthritis, excessive catabolism and lack of assimilation are evident, which leads to an imbalance in metabolic equilibrium. For example, it is known that if catabolic activity by cartilage cells increases, catabolic activity in the articular cartilage matrix exceeds anabolic activity, the structural destruction of prothioglycans and type II collagen may cause a decrease in the overall matrix. have.

To date, it is known that it is very difficult to restore a joint that has already undergone degenerative changes to a normal joint, and there are several limitations in the treatment of osteoarthritis.

Specifically, in relation to surgical treatment, the surgical method by arthroscopy does not have a constant effect, and in the case of artificial arthroplasty, the life of the artificial joint is limited, which requires further revision surgery. There is a problem that can cause complications such as bleeding or infection in the process.

Until recently, conservative treatments such as drug therapy related to the treatment of osteoarthritis have been mainly performed to prevent the progression of additional arthritis by alleviating symptoms or improving the deterioration factors of arthritis such as lifestyle and overweight. For example, it is known that the administration of a sufficient amount of the glucosamine compound may result in the protection or actual qualitative improvement of the cartilage in the joint showing the finding of osteoarthritis. In particular, glucosamine sulfate, one of the basic components of the disaccharide unit of glycosaminoglycans (GAG), has been shown to significantly promote prothioglycan production in chondrocytes. However, it is known that the glucosamine compound has relatively little effect on the production of type II collagen.

Accordingly, research on alternative therapies using natural-derived active ingredients that can restore osteoarthritis, that is, restore joints or restore joints, is being actively conducted without other side effects.

Bone tissue is a very complex and active tissue composed of extracellular matrix composed of minerals such as collagen fibers and hydroxyapatite, and various types of cells such as osteoblasts, osteoclasts, and osteoblasts. Through the action of osteoclasts, the process of aggregate formation is repeated by forming and absorbing continuously throughout life.

The collagen fiber is one of the most elements constituting the human body, and is widely distributed not only in bone but also in connective tissues such as the dermis, ligaments, tendons, cartilage, fascia, or blood vessels. The main component of the collagen fiber is a light fiber protein called collagen. Pyridinoline (pyridinoline) and dioxypyridinoline, the mature crosslinking material of collagen, are liberated and excreted in urine upon bone destruction by osteoclasts, and they are mainly present in bone and cartilage. It is used clinically as a reliable biomaker for the evaluation of osteolysis in various pathologies such as osteoarthritis.

The aggregate formation process is various growth factors secreted from bone tissues such as hormones such as parathyroid hormone (PTH), calcitonin (calcitonin), estrogen, and IGF-I (insulinlike growth factor I), and TNF-α (tumor necrosis factor-α). Through cytokines such as to control the balance of activity of osteoblasts and osteoclasts and maintains homeostasis.

However, metabolic metabolism occurs when osteoblast activity decreases with changes in genetic, physiological and environmental factors, resulting in decreased bone formation, increased bone resorption due to enhanced osteoclast activity, or when both factors act simultaneously. The disease will develop.

Osteoporosis is a representative bone metabolic disease, meaning a metabolic bone disease whose primary lesion is a quantitative decrease in the constituents of bone with significantly reduced bone mass compared to normal people of the same age and gender. Riggs and Melton have classified osteoporosis after age 50 as either type 1 osteoporosis (menopausal osteoporosis, postmenopausal osteoporosis) or primary and type 2 osteoporosis (senile osteoporosis) or secondary osteoporosis. .

The postmenopausal osteoporosis is osteoporosis due to estrogen deficiency, and refers to a disease in which fracture is easily caused due to a decrease in mineral composition of bone and a change in composition of collagen fibers due to estrogen deficiency.

Currently, calcium supplements, vitamin D metabolites and thiazide diuretics, calcitonin therapy, bisphosphonate therapy, and estrogen therapy are used to treat osteoporosis. Since there is no drug present, osteoporosis is more important than prevention.

In addition, estrogen-like substances used for the treatment of postmenopausal osteoporosis may cause side effects such as nausea, weight gain, irregular uterine bleeding, endometrial cancer and breast cancer with prolonged use, and in recent years, other side effects to compensate for the risk. Research on alternative therapies using natural ingredients derived from herbals and foods that can promote bone formation while minimizing bone loss has been actively conducted.

Alginic acid (alginate), alginic acid is α-L-guluronate and C5 epimer β-D-manneuronic acid (1,4'-β-D-mannuronate) is α-1, Heteropolysaccharide consisting of four bonds or β-1,4 bonds, is a complex glycopolymer combined in pG block (polyguluronate block), pM block (polymannuronate block) and pM / G stretch form.

Since the alginic acid mainly constitutes the cell wall of brown algae, it can be obtained by extracting from brown algae. The alginic acid has been used extensively since ancient times for its unique physical properties such as gel forming ability, high viscosity, and film forming ability.

For example, it is used as a stabilizer, viscous or gelling agent in various industries including food industry, printing industry and pharmaceutical industry, as raw material of drug delivery system such as microspheres, beads, microcapsules or tablets, matrix in tissue engineering It has been used as a carrier and the like.

In addition, alginic acid has been reported to have various physiological activities such as restraining obesity, healing constipation through promoting intestinal peristalsis, inhibiting anti-cholesterol, absorbing and removing heavy metals in the body, or inhibiting the toxicity of harmful substances. Research is underway to utilize it.

In addition, it is known to have a physiological activity effect such as wound dressings and hemostasis to protect the wound, as well as a variety of bioregulatory functions such as antimicrobial / anticancer activity, immune enhancement, anticholesterol effect, anticoagulant effect of alginic acid-derived oligosaccharides. Has been reported.

It is an object of the present invention to provide a composition for treating, improving or preventing osteoarthritis comprising a natural substance that is harmless to the human body as an active ingredient.

In order to achieve the above object, the present invention provides a composition for treating or preventing osteoarthritis or osteoporosis comprising alginic acid as an active ingredient.

The alginic acid may be an average weight average molecular weight (Mw) of the alginic acid is 1,500 to 5,000, preferably 2,400 to 2,600.

The alginic acid may have an average weight average molecular weight (Mw) of alginic acid of 1,500 to 5,000, and a weight ratio (M / G) of manneuronate and gluronate of alginic acid to 2.0 to 3.4, preferably 2.3 to 2.7. .

The alginic acid may be a weight ratio (M / G) of manneuronate and gluronate of alginic acid is 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.3 to 2.7.

In addition, the present invention provides a food composition for preventing or improving osteoarthritis or osteoporosis comprising alginic acid as an active ingredient to achieve the above object. The food composition may be a food, a food additive or a beverage.

The alginic acid may have an average weight average molecular weight (Mw) of alginic acid of 1,500 to 5,000, and a weight ratio (M / G) of mannuronate and gluronate of alginic acid to 1.6 to 3.8.

In addition, the alginic acid has an average weight average molecular weight (Mw) of alginic acid is 1,500 to 5,000, and the weight ratio (M / G) of mannuronate and gluronate of alginic acid is 1.6 to 3.8, preferably 2.0 to 3.4, more Preferably it may be 2.3 to 2.7.

In addition, the present invention provides a use of alginic acid, specifically for treating, improving or preventing alginic osteoarthritis or osteoporosis in order to achieve the above object.

The alginic acid has an average weight average molecular weight (Mw) of alginic acid is 1,500 to 5,000, the weight ratio (M / G) of manneuronate and gluronate of alginic acid is 1.6 to 3.8, preferably 2.0 to 3.4, more preferably May be from 2.3 to 2.7.

Hereinafter, the present invention will be described in more detail.

The inventors of the present invention have been searching for substances derived from natural products that can promote the production of collagen and proteoglycans while researching substances derived from natural products that have the effect of treating, improving or preventing osteoarthritis or osteoporosis, which have ensured human safety. Alginic acid, a natural product that can be extracted from brown algae in the process, promotes collagen production and production of proteoglycans according to the molecular weight and the ratio of constituent sugars mannuronate (M) and gluuronate (G). It was confirmed that the promoting ability was different.

Specifically, when the weight average molecular weight (Mw) is 2,500, the production of collagen and proteoglycans is significantly promoted compared to the case where the weight average molecular weight is 98,000, and mannuronate (M) and gluro included in the alginic acid. The ratio of guluronate (G) was found to have the best collagen production promoting ability and proteoglycan production promoting ability in the range of 2.5 to 3.2, most preferably 2.5, based on the weight ratio. As a result of checking whether the damage was improved, the ratio of mannuronate to gluronate was 2.5: 1 (manneuronate: gluronate) to 3.2: 1 (manneuronate: gluronate) based on the weight ratio. It is confirmed that the alginate, which is preferably 2.5: 1 (manneuronate: gluronate), has the best effect of improving joint damage, thereby completing the present invention. The.

The present invention relates to a composition for treating or preventing osteoarthritis or osteoporosis comprising alginic acid as an active ingredient.

The alginic acid may be an average weight average molecular weight (Mw) of the alginic acid is 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, even more preferably 2,400 to 2,600.

The molecular weight (g / mol) may be an average molecular weight, and the measured molecular weight is a weight average molecular weight (Mw).

The alginic acid has a ratio of mannuronate (M) and gluuronate (G) in a weight ratio of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, even more preferably based on weight ratio. 2.5 to 3.2 or 2.3 to 2.7, most preferably 2.5.

In this sense, the alginic acid is the ratio of mannuronate (M) and gluuronate (G), that is, the ratio of mannuronate (M) to gluuronate (G) based on weight. The ratio is 1.6 to 3.8: 1 (manneuronate: gluronate), preferably 2.0 to 3.4: 1 (manneuronate: gluronate), more preferably 2.2 to 3.2: 1 (manneuronate: glue) Ronateates), even more preferably 2.5 to 3.2: 1 (manneuronate: gluronate) or 2.3 to 2.7: 1 (manneuronate: gluronate), most preferably 2.5: 1 (manneuronate: Gluronate).

In addition, the alginic acid has a weight average molecular weight (Mw) of 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, still more preferably 2,400 to 2,600, mannuronate is a constituent sugar constituting the alginic acid The ratio of (mannuronate, M) and guluronate (G) is 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, even more preferably 2.5 to 3.2 or 2.3 to 2.3 by weight 2.7, most preferably 2.5.

Alginate of the present invention, in addition to the above components, nutrients, vitamins, electrolytes, flavors, coloring agents, neutralizing agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, It may be a composition comprising alginic acid further containing an alcohol, a carbonation agent used in the carbonated beverage. The components comprising the alginic acid may be added independently or in combination. The content of the additional component may be preferably added in the range of 0.1 to 20,000 parts by weight per 100 parts by weight of the alginic acid.

In the present invention, osteoarthrits refer to a disease in which inflammation and pain occur due to damage to bones and ligaments forming joints due to damage or degenerative changes immediately before point of cartilage protecting the joints.

In the present invention, osteoarthritis may include degenerative arthritis, rheumatoid arthritis, osteoarthritis or degenerative joint disease, and for example, may be degenerative arthritis.

Osteoarthritis is known to cause cartilage destruction due to an imbalance in metabolic mechanisms associated with assimilation and catabolism in the articular cartilage matrix. For example, it is known that if catabolic activity by cartilage cells increases, catabolic activity in the articular cartilage matrix exceeds anabolic activity, the structural destruction of prothioglycans and type II collagen may cause a decrease in the overall matrix. have.

In relation to the progression of osteoarthritis, type II collagen and prothioglyce by the production of nitric oxide, which causes inflammation in the cartilage matrix, the production of interleukin-1 (IL-1) or matrix metalloproteinases (MMPs) The suppression or destruction of cell production negatively affects the cartilage matrix, which in turn promotes degeneration of the osteoarthritis or the development or progression of osteoarthritis.

The degenerative arthritis is a degenerative non-inflammatory disease occurring in the macula, and the degenerative arthritis is classified into idiopathic arthritis or secondary arthritis.

Idiopathic arthritis is caused by factors such as age, sex, genetic factors, obesity, or a specific joint area without a particular organic cause, and is called primary arthritis. The secondary arthritis is caused by trauma, disease, and malformation that can damage joint cartilage, and refers to a case where articular cartilage is destroyed by bacterial arthritis or tuberculous arthritis, or after severe shock or repeated minor trauma. It is called secondary arthritis.

Osteoporosis is also referred to as osteoporosis or osteoporosis, and means a metabolic bone disease in which the quantitative decrease in the constituents of the bone is the main lesion in a state in which the bone mass is significantly reduced compared to normal people of the same age and gender.

In the present invention, osteoporosis may include postmenopausal osteoporosis, senile osteoporosis and bone fragility, preferably menopausal osteoporosis.

The osteoporosis is mainly accompanied by a thinning and weakening of the bones due to a decrease in bone tissue due to a hole in the bone or a decrease in calcium salt. Therefore, patients with osteoporosis are more likely to fracture bones.

Osteoporosis, in particular menopausal osteoporosis, is known to be associated with a decrease in estrogen secretion. More specifically, in the menopause state where menstruation does not occur, the secretion of estrogen, a female hormone, decreases, and the decrease of the secretion amount of estrogen increases bone osteoclast (osteoclast) activity to promote bone destruction and bone loss. It is reported to reduce calcium deposition and to reduce the amount of collagen produced.

More specifically, the supply of calcium (Ca) and the synthesis of collagen (Collagen) is essential for bone formation, but in menopause, that is, menopausal osteoporosis in women associated with bone absorption rather than the formation of bone itself in the body Due to the abnormal hormonal phenomenon of, it is reported that the inhibition of collagen synthesis due to the lack of estrogen rather than the lack of calcium.

In other words, the lack of estrogen due to menopause has been reported to reduce the synthesis of collagen and decrease the bone deposition of calcium, thereby increasing the bone absorption can lead to osteoporosis. Therefore, menopausal osteoporosis has not been reported to be able to cure it simply by dietary intake of calcium.

Alginic acid of the invention, in particular, alginate having a ratio of 2.5 or 3.2 of mannuronate (M) and gluuronate (G), corresponds to the corresponding mannuronate (M) and gluuronate (G). Compared with alginic acid having a ratio of less than 2.5 or more than 3.2, it was confirmed that the bone joint improvement function and the bone formation function were excellent. Specifically, as a result of confirming through the chondrocytes, it was confirmed that it can promote the synthesis of collagen and the synthesis of proteoglycans, and confirmed using the experimental animals that induced osteoarthrosis, it was confirmed that the regeneration of bone tissue can be improved.

The composition for preventing or treating osteoarthritis or osteoporosis of the present invention may include 0.001 to 99.99% by weight, preferably 0.1 to 99% by weight of the alginic acid, based on the total weight of the composition, and prevent or treat the osteoarthritis or osteoporosis. The content of the active ingredient can be appropriately adjusted depending on the method of use and purpose of use.

The composition includes nutrients, vitamins, electrolytes, flavors, colorants, neutralizers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acids, in addition to alginic acid. The carbonation agent etc. which are used for a drink can be contained further. The components may be added to the composition independently or in combination. The content of the additional component may be preferably added in the range of 0.1 to 20 parts by weight per 100 parts by weight of the alginic acid.

The composition for treating or preventing osteoarthritis or osteoporosis comprising the alginic acid as an active ingredient may be a pharmaceutical composition or a pharmaceutical composition for treating or preventing osteoarthritis or osteoporosis.

In this aspect, the present invention may be a pharmaceutical composition containing the alginic acid as an active ingredient, and having a therapeutic or prophylactic effect of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis-related diseases.

The pharmaceutical composition for the treatment or prevention of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis-related diseases comprising the alginic acid of the present invention is 0.001 to 99.99% by weight, preferably 0.1 to 99% by weight, based on the total weight of the composition. It may include.

The composition for the prevention or treatment of osteoarthritis or osteoporosis or a disease related to osteoarthritis or osteoporosis may further include appropriate carriers, excipients and diluents commonly used in the preparation thereof.

Pharmaceutical compositions for the prevention or treatment of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis-related diseases comprising the alginic acid as an active ingredient, respectively, according to conventional methods, oral formulations such as powders, granules, tablets, suspensions, emulsions, syrups, etc. Can be used.

As carriers, excipients and diluents that can be included in the pharmaceutical composition for the prevention or treatment of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis related diseases including alginic acid as an active ingredient, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol , Maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium Stearates and mineral oils.

When the pharmaceutical composition for the prevention or treatment of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis-related diseases containing the alginic acid as an active ingredient is a solid preparation for oral administration, tablets, pills, powders, granules, capsules, and the like are included. Solid preparations are prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like in the extract. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

In addition, when the pharmaceutical composition for the prevention or treatment of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis-related diseases is a liquid preparation for oral administration, the liquid preparation includes a suspension, a solution, an emulsion, a syrup, and the like. In addition to water, liquid paraffin, which is a simple diluent, various excipients may be included, for example, wetting agents, sweeteners, fragrances, preservatives, and the like.

The preferred dosage of the pharmaceutical composition for the prevention or treatment of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis-related diseases including the alginic acid as an active ingredient varies depending on the condition and weight, the degree of the disease, the form of the drug, the route of administration, and the duration. Can be appropriately selected. Preferably from 0.0001 to 1000 mg / kg per day based on the alginic acid of the present invention, to be more effective may be administered in 0.01 to 100 mg / kg, but is not limited thereto. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

In another aspect, the present invention includes the alginic acid as an active ingredient, and may be a food composition having an improvement or prevention effect of osteoarthritis or osteoporosis or osteoarthritis or osteoporosis related diseases.

Alginic acid included in the food composition as an active ingredient may be an average weight average molecular weight (Mw) of the alginic acid is 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, even more preferably 2,400 to 2,600 have.

The alginic acid has a ratio (M / G) of mannuronate (M) and gluuronate (G) of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, based on the weight ratio. Even more preferably 2.5 to 3.2 or 2.3 to 2.7, most preferably 2.5.

Specifically, the alginic acid included in the food composition as an active ingredient has a weight average molecular weight (Mw) of 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, even more preferably 2,400 to 2,600, The ratio (M / G) of mannuronate (M) and gluuronate (G), which constitute the alginic acid, is 1.6 to 3.8, preferably 2.0 to 3.4, more preferably based on the weight ratio. 2.2 to 3.2, even more preferably 2.5 to 3.2 or 2.3 to 2.7, most preferably 2.5.

In the present specification, the term "food" means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through some processing process. It is intended to include all foods, food additives, health functional foods and beverages.

Examples of the food to which the alginic acid of the present invention can be added include various foods, beverages, gums, teas, vitamin complexes, and functional foods. In addition, the food in the present invention includes special nutritional products (e.g., prepared oils, infants, baby food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), health supplements, seasoned foods ( For example, soy sauce, miso, red pepper paste, mixed soy sauce), sauces, confectionery (e.g. snacks), dairy products (e.g. fermented milk, cheese, etc.), other processed foods, kimchi, pickles (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruits, vegetable drinks, soy milk, fermented beverages, and the like, and natural seasonings (eg, ramen soup).

The food, beverage or food additives may be prepared by a conventional manufacturing method.

Functional food in the present invention is the control of biological defense rhythm, disease prevention and recovery of food groups or food compositions that have added value to the food by using physical, biochemical, biotechnological techniques, etc. It means a food processed and designed to fully express the gymnastics function related to the living body.

The functional food may include food acceptable food additives, and may further include appropriate carriers, excipients and diluents commonly used in the manufacture of functional foods.

In the present invention, the drink is a generic term for drinking to quench thirst or to enjoy the taste and is intended to include a functional drink.

The beverage is not particularly limited to other ingredients other than including the alginic acid as an active ingredient in the indicated proportions as an active ingredient, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.

Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .

The proportion of such natural carbohydrates is generally about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the composition of the present invention. In addition, the composition of the present invention may further contain a pulp for the production of natural fruit juices, fruit juice drinks, vegetable drinks.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.

These components can be used independently or in combination. The proportion of such additives is not so critical, but may be selected in the range of 0 to 20,000 parts by weight per 100 parts by weight of the alginic acid of the present invention.

Functional beverage in the present invention is a biological defense rhythm control, disease prevention and the like having a beverage group or a beverage composition that has added value to the beverage by using physical, biochemical, biotechnological techniques, etc. to function and express the function of the beverage to a specific purpose Means a beverage that is designed and processed to fully express the gymnastics function related to recovery.

The functional beverage is not particularly limited to other ingredients except for containing the alginic acid of the present invention as an essential ingredient in the ratio indicated, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.

The proportion of the natural carbohydrate may generally be about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the composition of the present invention.

In addition, in the food composition for the purpose of improving or preventing osteoarthritis or osteoporosis, the amount of the alginic acid may comprise from 0.01% to 15% by weight of the total food weight, the beverage composition from 0.02 g to 100 ml based on 5 g, preferably 0.3 g to 1 g.

The present invention also relates to the use of alginic acid, in particular to the use of alginic acid for the treatment, amelioration or prevention of osteoarthritis or osteoporosis.

The alginic acid has an average weight average molecular weight (Mw) of alginic acid is 1,500 to 5,000, the weight ratio (M / G) of manneuronate and gluronate of alginic acid is 1.6 to 3.8, preferably 2.0 to 3.4, more preferably May be 2.2 to 3.2, even more preferably 2.5 to 3.2 or 2.3 to 2.7, most preferably 2.5.

The alginic acid has a weight ratio (M / G) of manneuronate and gluronate of alginic acid of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, still more preferably 2.5 to 3.2 or 2.3 to 2.7, most preferably 2.5.

The alginic acid, specifically, the weight average molecular weight (Mw) is 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, even more preferably 2,400 to 2,600, mannuro is a constituent sugar constituting the alginic acid The ratio of mannuronate (M) and gluuronate (G) is 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, even more preferably 2.5 to 3.2 or 2.3 based on the weight ratio. Alginic acid of from 2.7 to 2.7, most preferably 2.5, has significantly superior collagen production and proteoglycan production promoting properties in chondrocytes compared to alginic acid having a different range of molecular weight or different ranges of mannuronate and gluronate. Has osteoarthritis or osteoporosis or osteoarthritis or osteoporosis, such as degenerative osteoarthritis It is evaluated to be of excellent use for the treatment, amelioration or prevention of related diseases.

Alginic acid of the present invention, as a result of experiments using chondrocytes, has a significantly superior collagen synthesis promoting ability and proteoglycan synthesis promoting ability, compared to alginic acid having a molecular weight or weight ratio of mannuronate and gluronate in different ranges, osteoarthritis As a result of the animal experiments that induced the results, it was confirmed that the ability to improve osteoarthritis was remarkably excellent, and the alginate as the active ingredient can be prepared from brown algae, which is an algae used as a food, and is expected to have no problems with side effects. Or as a new prophylactic or therapeutic agent such as osteoporosis is expected to be very valuable.

1 to 6 is a picture confirming the improvement of osteoarthritis of the experimental animal according to the alginic acid type according to an embodiment of the present invention, Figure 1 is a control group administered with placebo, Figure 2 is the manneuronate and glue of alginic acid It is a photograph of the joint surface of the femur of the experimental animal administered alginic acid with a weight ratio (M / G) of launate, and FIG. 3 is a weight ratio (M / G) of mannuronate and gluronate of alginic acid. This is a photograph of the joint surface of the thigh of the experimental animal administered with the alginic acid of 1.6, Figure 4 is a test animal administered with alginic acid having a weight ratio (M / G) of mannuronate and gluronate of alginic acid of 2.5 Figure 5 is a photograph of the joint surface of the femoral part, Figure 5 is a photograph of the joint surface of the femoral section of the experimental animal administered alginic acid having a weight ratio (M / G) of alginate mannuronate and gluronate of 3.2, Figure 6 Manneuronate and glurone of alginic acid The weight ratio of agent (M / G) is a photograph taken of the femoral articular surface of the experimental animals treated with 3.8 of alginic acid.

Hereinafter, preferred embodiments of the present invention are described. The following examples are only for illustrating the present invention and the scope of the present invention is not limited by the following examples.

실시예 1: 알긴산 올리고당의 제조Example 1 Preparation of Alginic Acid Oligosaccharides

Using a 5 L fermentation tube, 150 g of sodium alginate having a weight average molecular weight (Mw) of 100,000 to 500,000 was added to 3,000 ml of distilled water, and sodium alginate was completely dissolved to prepare an aqueous sodium alginate solution. It was.

After fixing the temperature of the fermentation tube at 35 ° C., 15 mg (3,500 unit / g) of alginate lyase (alginate lyase, sigma, USA,) was added, followed by a decomposition reaction for 20 hours.

After the decomposition reaction, the temperature of the fermentation tube was raised to 90 ° C. to stop the decomposition reaction by the enzyme, and the aqueous sodium alginate solution was cooled by circulating the cooling water. Filtration was performed using an ultrafiltration membrane (Millipore UF filtration, MWCO 10,000) in order to obtain alginic acid according to each molecular weight range from the aqueous alginic acid solution subjected to the decomposition reaction by the enzyme.

The molecular weight of the alginic acid obtained by the ultrafiltration membrane was measured by GPC (Gel Permeation Chromatography), and it was confirmed that the mass average molecular weight (Mw) of the alginic acid was 2,500.

In addition, for alginic acid having an alginate mass average molecular weight (Mw) of 98,000 and 2,500, the ratios of mannuronate (M) and gluuronate (G) were respectively measured based on the weight ratio.

The weight ratio (M / G ratio) of the alginate to mannuronate and gluronate is poly-mannuronic acid (PMA) and polygluronate (poly-guluronic acid, PGA) from alginate. After partial extraction, the weight was measured after lyophilization, and the weight ratio (M / G weigh ratio) of mannuronate and gluronate was determined.

Partial acid hydrolysis of the poly-mannuronic acid (poly-mannuronic acid, PMA) and polygluronate (poly-guluronic acid, PGA) was performed using a method such as Mahesh.

Specifically, 125 ml of 0.25MH ₂ SO ₄ was added to 5 g of alginic acid, and the alginic acid was dissolved well, and then the maximum power (700W) was obtained using a microwave oven (Microwave, MR-208, LG Electronics, Korea). Heated for minutes. The heated alginic acid solution was cooled to room temperature, and then filtered using a filter paper (Whatman NO. 4). After filtration, the obtained residue was dissolved in 0.1M Na ₂ CO ₃ . The pH of the solution was adjusted to pH 2.85 using 0.1 M HCl, and then, poly-gluuronic acid (PGA) was obtained by recovering the precipitate through centrifugation. In addition, after centrifugation, the pH of the obtained supernatant was adjusted to pH 1.5 using 0.1 M HCl, and then the precipitate was recovered by centrifugation. Poly-mannuronic acid (poly-mannuronic acid, PMA) was precipitated. ) Was obtained.

The obtained polygluronate and poly manneuronate were each neutralized to pH 7.0, and then lyophilized at −80 ° C. to determine the respective weights, and the weight ratio (M / G ratio) of manneuronate and gluronate was measured. ) Was determined.

실시예 2: 연골세포 배양Example 2: Chondrocyte Culture

Cartilage was collected from the knee joints of two-week-old rabbits (Korea Research Institute of Life Science, Korea), and submerged in the culture medium, specifically, 1.6 ml of serum-free DMEM (Pharmacia Biotech. USA), followed by 1% collagenase. 0.4 ml (Sigma, USA) was added.

The culture solution containing cartilage added with collagenase was placed in a CO ₂ incubator at 37 ° C., followed by a reaction for about 6 hours while shaking the cells every 30 minutes to decompose collagen in the cartilage tissue with collagenase, Chondrocytes of chondrocytes were separated into single cell units. After the above procedure, the supernatant was discarded by centrifuging the culture solution containing cartilage, and 1 ml of complete medium (serum-containing DMEM) was added and diluted in 2 ml of normal medium (10% FBS DMEM) per rabbit. To make a cell suspension.

After counting the number of cells in the cell suspension, dilute with normal medium (10% FBS DMEM) to a cell density of 0.5 x 10 ⁵ cells / cm ² , and the cell culture solution prepared in the dilution to each dish (dish) After dispensing, it was used for the experiment.

실시예 3: 알긴산의 타입 Ⅱ 콜라겐의 합성 증진에 대한 효과Example 3: Effect of Alginic Acid on Synthesis of Type II Collagen

Each dish containing chondrocytes dispensed in Example 2 was treated with a control group (untreated group), low molecular weight alginic acid (average molecular weight 2,500, M / G ratio 1.6), and polymer alginic acid (average molecular weight 98,000, M / G ratio 1.6). Divided into treatment groups, the control group was not treated at all, and the low molecular weight alginic acid treatment group and the polymer alginic acid treatment group respectively treated the alginic acid by 100 mg / L, and then the control group, the low molecular weight alginic acid treatment group and the polymer alginic acid treatment group. 48 hours of incubation at 37 ℃ CO ₂ incubator. After the incubation, Western blotting was performed using an antibody against collagen (Chemicon international, USA) (Peter B. Kaufma et al ., Molecular and Cellular Methods Biology and Medicine, 108-121, CRCpress).

The amount of protein expressed was confirmed using the film obtained as a result of Western blotting, and image J 2.0 program (Quantity One) was used to quantitatively analyze the expression of the identified protein., BIO-RAD, USA) was used to measure the amount of β-actin used as internal protein and type II collagen expressed by each target protein. In the quantification process, the content of type II collagen and β-actin in the sample in the control group was determined by calibrator. The experiment was repeated three times in total, and the quantitative results of the three repeated results are shown in Table 1 below.

Table 1

division	Control	Polymer Alginate	Low Molecular Alginate
Relative Expression Level (Collagen type II / actin)	1.11	1.21	2.52
	0.85	1.10	2.74
	1.05	1.11	2.65

As shown in Table 1, it was confirmed that the expression of type II collagen by chondrocytes in the low molecular weight alginic acid treated group was significantly increased compared to the control group. However, when the polymer alginic acid was treated, it was confirmed that there is little change in the expression level of type II collagen compared to the control.

From the above results, it was confirmed that low molecular weight alginic acid activates chondrocytes to enhance type II collagen synthesis, whereas high molecular weight alginic acid has a minor effect on type II collagen synthesis.

실시예 4: 알긴산의 프로테오글리칸의 합성 증진에 대한 효과Example 4 Effect of Alginic Acid on Synthesis of Proteoglycans

In order to analyze the effect on the synthesis of proteoglycans forming the cartilage matrix according to the alginic acid molecular weight, as in Example 3, divided into a control group (untreated group), a low molecular alginic acid treatment group and a polymer alginic acid treatment group, Alcian blue The amount of proteoglycans was measured by an Alcian Blue staining assay.

Specifically, as in Example 3, the control group is not treated at all, and the low molecular weight alginic acid treatment group and the polymer alginic acid treatment group are each treated with 100 mg / L of the alginic acid, the control group, low molecular weight alginic acid treatment group and The polymer alginic acid treated group was incubated for 48 hours in a CO ₂ incubator at 37 ℃, the OD value of the culture was measured. The experiment was repeated three times in total, and the quantitative results of the three repeated results are shown in Table 2 below.

TABLE 2

division	Control	Polymer Alginate	Low Molecular Alginate
Proteoglycan Concentration (OD)	0.245	0.255	0.345
	0.235	0.231	0.386
	0.263	0.268	0.441

As shown in Table 2, as a result of performing an Alcian blue staining to measure proteoglycan, which is a cartilage matrix molecule, the amount of proteoglycan was significantly increased in the low molecular weight alginic acid treated group compared to the control group, but in the case of the polymer alginic acid treated group, It was found that the amount of proteoglycans did not increase significantly.

From the above results, it was confirmed that low molecular weight alginic acid promotes the synthesis of proteoglycans by chondrocytes, whereas high molecular weight alginic acid does not affect the synthesis of proteoglycans.

실시예 5: 알긴산의 M/G 비율에 따른 콜라겐의 합성 증진에 대한 효과Example 5 Effect on Synthesis of Collagen According to M / G Ratio of Alginic Acid

In the low molecular weight alginic acid (mass average molecular weight (Mw) 2,500) confirmed to promote collagen synthesis in Example 3, the ratio of mannuronate (M) and gluuronate (G) constituting the alginic acid Was divided into the weight ratio (M / G) of gluronate and mannuronate, and the following experiment was performed to confirm collagen synthesis ability according to the weight ratio (M / G).

First, each alginic acid is treated in a dish containing chondrocytes as in Example 3, and a low molecular weight alginic acid having a M / G ratio of 1.1, 1.6, 2.1 and 2.5 and a control (untreated group) without any sample treatment, respectively. After dividing into groups treated with 100 mg / L each, low molecular weight alginic acid was treated, and then cultured for 48 hours at 37 ° C. using a CO ₂ incubator. After the cultivation, Western blotting was carried out in the same manner as in Example 3, and after measuring the amount of collagen with respect to the amount of β-actin used as internal control, each protein of the control group was determined as a calibrator, The expression level of type II collagen according to the weight ratio (M / G) of gluronate to mannuronate was measured and shown in Table 3.

TABLE 3

division	Control	Low Molecular Alginate
		M / G ratio
		1.1	1.6	2.1	2.5	3.2	3.8
Relative Expression Level (Collagen type II / actin)	1.02	1.04	1.87	2.15	2.74	2.81	1.90
	0.98	1.15	1.75	2.25	2.61	2.57	1.94
	0.94	1.21	1.81	2.14	2.71	2.70	1.89

As shown in Table 3, when the low-molecular alginic acid was added compared to the control, it was confirmed that the amount of collagen synthesis increased. In particular, the amount of collagen synthesis increases as the weight ratio (M / G) of mannuronate to the gluronate of alginic acid increases, adding alginic acid having a weight ratio (M / G) of gluronate and mannuronate of alginic acid to 2.5 In one case, it was found that the amount of collagen synthesis was the highest, and when the weight ratio (M / G) of mannuronate to the gluronate of alginic acid was 3.2, the weight ratio (M / G) of mannuronate to gluronate of alginic acid was 2.5. Although the degree was almost similar to that, it was confirmed that the collagen synthesis amount was remarkably decreased at 3.8 weight ratio of manneuronate to gluronate of alginic acid (M / G).

From the above results, the weight ratio (M / G) of mannuronate to gluronate was higher in collagen production than in the case of adding no alginic acid or the polymer alginic acid identified in Example 3 in the range of 1.6 to 3.8, The weight ratio (M / G) of mannuronate to gluronate suitable for promoting the production of collagen synthesis was found to be markedly excellent collagen production promoting ability compared to the case outside the above range in the range of 2.5 to 3.2, The weight ratio (M / G) of neuronate was found to have the best collagen production promoting ability in the case of 2.5.

실시예 6: 알긴산의 M/G 비율에 따른 프로테오글리칸의 합성 증진에 대한 효과Example 6 Effect on Synthesis of Proteoglycans According to M / G Ratio of Alginic Acid

The effect of the low molecular weight algiic acid of the present invention on the synthesis of proteoglycans forming the cartilage matrix was analyzed. Alcian Blue staining assay was performed to determine the amount of proteoglycans.

In the low molecular weight alginic acid (mass average molecular weight (Mw) 2,500) confirmed to promote the production of proteoglycans in Example 4, mannuronate (M) and gluuronate constituting the alginic acid as in Example 5 In order to confirm the ability to promote proteoglycan production according to the weight ratio (M / G) of G), the following experiment was performed.

First, chondrocytes divided into a group treated with 100 mg / L of low-molecular alginic acid with M / G ratios of 1.1, 1.6, 2.1, and 2.5, respectively, which were not treated with any sample as in Example 5. Was incubated for 48 hours at 37 ℃ using a CO ₂ incubator. As in Example 4, the OD value of the culture solution was measured after the culture, and the results are shown in Table 4 below.

Table 4

division	Control	Low Molecular Alginate
		M / G ratio
		1.1	1.6	2.1	2.5	3.2	3.8
Proteoglycan Concentration (OD)	0.265	0.278	0.355	0.411	0.436	0.432	0.375
	0.245	0.262	0.388	0.414	0.431	0.430	0.404
	0.249	0.264	0.395	0.425	0.445	0.446	0.411

As shown in Table 4, when the low-molecular alginic acid was added as compared to the control, it was confirmed that the amount of proteoglycans was increased. In particular, the production of proteoglycans increases as the weight ratio of manneuronate to gluronate of alginic acid increases (M / G), and the alginic acid having a weight ratio (M / G) of manneuron to gluronate of alginic acid is added 2.5. In one case, proteoglycan production was found to be the highest, and the ratio of manneuronate to gluronate of alginic acid (M / G) was 3.2, and the ratio of manneuronate to gluronate of alginic acid (M / G) was 2.5. Although almost similar to, the weight ratio (M / G) of mannuronate to gluronate of alginic acid was again found to be significantly reduced proteoglycan production at 3.8.

From the above results, the weight ratio of mannuronate to gluronate (M / G) was found to be higher in proteoglycan production than in the case of addition of no alginic acid or the polymer alginic acid identified in Example 3 in the range of 1.6 to 3.8, proteoglycan The weight ratio (M / G) of mannuronate to gluronate suitable for promoting the production was confirmed to be significantly superior to the proteoglycan production promoting ability compared to the case outside the above range in the range of 2.1 to 3.2, more specifically 2.5 to 3.2, The weight ratio (M / G) of mannuronate to roronate was found to have the best proteoglycan production promoting ability in the case of 2.5.

실시예 7: 동물모델을 이용한 골관절염 치료 효능 분석Example 7 Analysis of Osteoarthritis Treatment Efficacy Using Animal Model

Example 7-1 Breeding of Experimental Animals

Thirty New Zealand white rabbits weighing 3 kg to 3.5 kg (New Zealand white rabbit, Magnetic, Korea Life Science Research Institute, Korea) were divided into six groups of five animals, and were bred in separate iron cages. The experimental animals were bred under conditions of constant light and dark, light at 21 ° C. to 25 ° C. and relative humidity of 45% to 65% from 7 am to 7 pm, and the feed of the experimental animals was general pellets. Dry feed (Korean experimental animals, Korea) was used, and feed and water were always available.

Example 7-2: Measurement of Osteoarthritis Treatment Efficacy

In order to confirm the therapeutic efficacy of the osteoarthritis, osteoarthritis was induced in the experimental animals bred in Example 6-1. The osteoarthritis was induced by the right cruciate ligament dissection method.

Specifically, xylazine hydrochloride (3 mg / kg) and ketamine hydrochloride (50 mg / kg) were injected intramuscularly to the experimental animal by general anesthesia. Disinfection was performed using% povidone-iodine solution. Of the right posterior part of the depilation and disinfection, the medial knee was exposed by 2 cm incision, the fascia and articular cap were incision, and the patella was folded outward to expose the cruciate ligament. The exposed cruciate ligament was excised using No. 11 blade, and then washed with physiological saline. After resection of the cruciate ligament, the patella was repositioned and the articular capsule and fascia were intermittently sutured with 4-0 absorbent sutures, and the skin was continuously and intermittently sutured with 3-0 nonabsorbable sutures. After disinfecting the suture with the 10% povidone-iodine solution, antibiotics (enrofloxacin) were injected subcutaneously at a content of 5 mg / kg (weight of the test animal).

Alginate was orally administered to the experimental animals that caused the osteoarthritis. The oral administration was performed by bending in five groups. First, the control group was administered 0.5 ml / kg (Body Weith, BW) of physiological saline, and as the experimental group the low molecular weight alginic acid (Mn) of 2,500 in Example 1 with mannuronate (mannuronate, M) and Gluronate (guluronate, G) by weight ratio (M / G) was administered orally divided as in Examples 5 and 6. Specifically, the low molecular weight alginic acid administered group having an M / G ratio of 1.1, the low molecular alginic acid administered group having an M / G ratio of 1.6, the low molecular alginic acid administered group having an M / G ratio of 2.5, the low molecular alginic acid administered group having an M / G ratio of 3.2, and the M / G ratio 3.8 Alginic acid type was divided into groups of low molecular weight alginic acid, and 30 mg / kg (BW) of each alginic acid was dissolved in 0.5 ml / kg (BW) physiological saline.

Both the control group and the experimental group were orally administered every day from the next day after surgery to the fifth week.

After oral administration for 5 weeks, all experimental animals belonging to the control group and the experimental group were anesthetized with xylazine and ketamine at 6 weeks after surgery, followed by euthanasia by injecting thiopental sodium intracardiacally and exposing the knee joint. The joint surfaces of the middle and lateral thighs were visually observed. Specifically, the depth of the cartilage defects was confirmed from the inside and outside of the femoral joints by applying Indian ink on the exposed femoral joint surface, and the severity of osteoarthritis was divided into four stages of 1 to 4 to give a score. .

Specifically, 1 indicates that the joint surface looks normal and ink is not applied, and 2 indicates that the surface looks normal but asks in the form of light gray spots when ink is applied, and 3 indicates that the joint surface is thick and dark black when ink is applied. Spots are formed and 4 indicates subchondral bones are revealed.

After the score was measured, the average of five experimental results for each group was calculated. For the purpose of objective comparison, two observers were examined by double blind method. The photographs taken of the cartilage defects of the observed experimental animals are shown in FIGS. 1 to 6, and the calculated average values are shown in Table 5 below.

Table 5

division	Control	Low Molecular Alginate
		M / G ratio
		1.1	1.6	2.5	3.2	3.8
Middle femur	3.65 ± 0.8	3.25 ± 0.5	2.90 ± 0.3	2.52 ± 0.3	2.62 ± 0.3	3.05 ± 0.4
Lateral femur	3.42 ± 0.5	3.16 ± 0.6	2.75 ± 0.5	2.22 ± 0.3	2.18 ± 0.3	2.98 ± 0.4
Total average	3.54 ± 0.7	3.21 ± 0.7	2.82 ± 0.4	2.37 ± 0.3	2.40 ± 0.3	3.02 ± 0.4

As shown in FIG. 1 and Table 5, when the low molecular weight alginic acid was added, a significant reduction in the severity of osteoarthritis was confirmed as compared to the control (FIG. 1).

Specifically, the weight ratio (M / G) of mannuronate to gluronate in the range of 1.6 to 3.8 (Figs. 3 to 6) without the addition of alginic acid, that is, a control group (Fig. 1) or gluronate administered saline with placebo Significant reduction in the severity of osteoarthritis was observed compared to the addition of alginic acid with a weight ratio (M / G) of mannuronate to 1.1 (FIG. 2), and a weight ratio (M / G) of mannuronate to gluronate was 2.5 (FIG. 2). In the range of 4) to 3.2 (FIG. 5), remarkably superior osteoarthritis improvement effect was confirmed, and the weight ratio (M / G) of gluronate to gluronate was 2.5 (FIG. 4). It was confirmed that the damage site of the whole cartilage was improved cleanly, and it was confirmed that it had the best osteoarthritis improving effect.

The results of Example 7 using the animal model were confirmed to have the same tendency as those of Examples 5 and 6 confirming collagen production promoting ability and proteoglycan production promoting ability in in vitro experiments ( invitro ).

Claims

A pharmaceutical composition for treating or preventing osteoarthritis comprising alginic acid as an active ingredient.
The method of claim 1,

The alginic acid is an average weight average molecular weight (Mw) of alginic acid is 1,500 to 5,000, the weight ratio (M / G) of the mannuronate and gluronate of alginic acid is 1.6 to 3.8 pharmaceutical composition for treating or preventing osteoarthritis.
The method of claim 2,

The alginic acid is a pharmaceutical composition for treating or preventing osteoarthritis, wherein the weight ratio (M / G) of manneuronate and gluronate of alginic acid is 2.0 to 3.4.
The method of claim 3, wherein

The alginic acid is a pharmaceutical composition for treating or preventing osteoarthritis, wherein the weight ratio (M / G) of manneuronate and gluronate of alginic acid is 2.3 to 2.7.
The method of claim 1,

The alginic acid is a pharmaceutical composition for treating or preventing osteoarthritis, wherein the weight ratio (M / G) of mannuronate and gluronate of alginic acid is 1.6 to 3.8.
The method of claim 5,

The alginic acid is a pharmaceutical composition for treating or preventing osteoarthritis, wherein the weight ratio (M / G) of manneuronate and gluronate of alginic acid is 2.0 to 3.4.
The method of claim 6,

The alginic acid is a pharmaceutical composition for treating or preventing osteoarthritis, wherein the weight ratio (M / G) of manneuronate and gluronate of alginic acid is 2.3 to 2.7.
A food composition for preventing or improving osteoarthritis comprising alginic acid having a weight ratio (M / G) of alginate and gluronate of alginic acid as 1.6 to 3.8 as an active ingredient.
The method of claim 8,

The average weight average molecular weight (Mw) of the alginic acid is 1,500 to 5,000 food composition for preventing or improving osteoarthritis.
The method of claim 8,

The food composition is a food composition for preventing or improving osteoarthritis that is a food, a food additive or a beverage.
A pharmaceutical composition for treating or preventing osteoporosis, comprising alginic acid having a weight ratio (M / G) of alginate to gluronate of 1.6 to 3.8 as an active ingredient.
The method of claim 11,

A pharmaceutical composition for treating or preventing osteoporosis, wherein the average weight average molecular weight (Mw) of the alginic acid is 1,500 to 5,000.
A food composition for preventing or improving osteoporosis comprising alginic acid having a weight ratio (M / G) of alginate and gluronate of alginic acid as 1.6 to 3.8 as an active ingredient.
The method of claim 13,

Food composition for preventing or improving osteoporosis, wherein the average weight average molecular weight (Mw) of the alginic acid is 1,500 to 5,000.
The food composition of claim 13, wherein the food composition is a food, a food additive or a beverage.